Skip to main content
. 2017 Jun 8;16:1176935117711944. doi: 10.1177/1176935117711944

Figure 2.

Figure 2

(A) HRAS expression also associates with mutation status. Sample subsets for each of the tumor types were prepared based on the HRAS mutation status. HRAS expression values were then plotted for each sample group. Sample numbers and P values are indicated on the plot. Lane 1—HRAS expression in HRAS WT samples from BLCA, lane 2—HRAS expression for HRAS-mutant samples from BLCA, lane 3—HRAS expression in HRAS WT samples from HNSC, lane 4—HRAS expression for HRAS-mutant samples from HNSC, lane 5—HRAS expression in HRAS WT samples from PCPG, lane 6—HRAS expression in HRAS-mutant samples from PCPG, lane 7—HRAS expression in HRAS WT samples from SKCM, HRAS expression in HRAS-mutant samples from SKCM. Lane 9—HRAS expression for HRAS WT samples from THYM, lane 10—HRAS expression for HRAS-mutant samples from THYM, lane 11—HRAS expression for HRAS WT samples from THCA, lane 12—HRAS expression from HRAS-mutant samples from THCA. (B) NRAS expression in SKCM sample subsets. Sample subsets were prepared for the total tumor set, the primary tumor set, and the metastatic sample set for both the NRAS WT and NRAS-mutant sample groups. Sample numbers for each group and t test P values are shown on the plot. Lane 1—NRAS expression in total NRAS WT subset of SKCM, lane 2—NRAS expression in NRAS-mutant samples from SKCM, lane 3—NRAS expression in NRAS WT primary tumor samples from SKCM, lane 4—NRAS expression in NRAS-mutant primary tumor samples from SKCM, lane 5—NRAS expression in NRAS WT metastatic tumor samples (mets) from SKCM, lane 6—NRAS expression in NRAS-mutant metastatic tumor samples (mets) from SKCM. BLCA indicates bladder cancer; HNSC, head and neck squamous cell; PCPG, pheochromocytoma and paraganglioma; SKCM, skin cutaneous melanoma; THCA, thyroid cancer; THYM, thymoma; WT, wild type.